IMUNON INC

IMUNON’s IMNN‑001 shows superior survival in advanced ovarian cancer with no systemic toxicity, promising a new, safer DNA‑mediated immunotherapy.

Imunon Inc. reports Q3 2025 results: R&D spend fell 42%, operating loss narrowed 30%, and Phase III ovarian‑cancer trial shows promising data, signalling a shift toward clinical milestones.

Imunon Inc. has completed a $9.75 million private placement, strengthening its financial position as it continues to advance innovative treatments for various human diseases.

Imunon Inc., a clinical-stage biotechnology company, is making significant strides in the healthcare sector with recent announcements of clinical trial progress and a potential $9.75 million private placement.

Imunon Inc. is navigating a pivotal moment, balancing innovative medical advancements with strategic financial decisions, as it presents promising data at ASCO 2025 and withdraws from a planned public offering.

Imunon Inc, a clinical-stage biotech company, faces financial challenges despite its ambitious mission to harness the body’s natural defenses to combat human diseases.

Imunon Inc. reported a GAAP earnings per share of -$0.28 for the first quarter of 2025, reflecting the company’s ongoing investments in clinical trials and research initiatives.